- Design
- Retrospective cohort with whole-exome and whole-transcriptome sequencing
- Population
- 90 intrahepatic cholangiocarcinomas, 25 FGFR2/3-altered
- Primary outcome
- Clinicopathological and molecular features; survival
- Effect
- Small-duct type 100% vs 32%; univariate DSS HR 0.29 (95% CI 0.09 to 0.95), not significant on multivariate
A retrospective study sequenced 90 intrahepatic cholangiocarcinomas with combined whole-exome and whole-transcriptome sequencing. Twenty-five (28%) carried FGFR2 or FGFR3 alterations, mostly FGFR2 fusions with a wide range of partners.
Compared with wild-type tumours, the FGFR2/3-altered group was younger (median 61 vs 68 years) and had larger tumours (9.6 vs 6.4 cm). All were small-duct type (100% vs 32%), they were mostly non-mucin-producing (84% vs 3%) and more often well differentiated. BAP1 alterations were more common and TP53 less common. Disease-specific survival was better on univariate analysis (HR 0.29, 95% CI 0.09 to 0.95) but not after adjustment.
For the reporting pathologist, the morphology is the useful part: a small-duct, non-mucinous intrahepatic cholangiocarcinoma is the tumour most likely to carry an FGFR2 fusion, which has targeted treatment options. That is a reason to make sure such tumours reach molecular testing.
The survival advantage did not survive multivariable analysis and the series is small, so it is not a prognostic marker on its own.
- Record small-duct versus large-duct type in intrahepatic cholangiocarcinoma reports.
- Note mucin production; non-mucinous small-duct tumours were enriched for FGFR2/3 alterations.
- Flag such tumours for comprehensive genomic profiling, including fusion detection.
- RNA-based testing helps catch the wide range of FGFR2 fusion partners.
Why it matters
Morphology can point the oncologist towards a targetable alteration.
The statistics, in plain English
A univariate hazard ratio of 0.29 suggested better survival, but after adjusting for other factors the estimate became 2.52 with a huge interval (0.14 to 45), meaning the data cannot tell either way.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for pathology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free